TABLE 3.
Treatment‐related adverse events observed with camrelizumab and apatinib plus chemotherapy
| Event | Number of patients [cases (%)] | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Reactive capillary hemangiomas | 18 (60.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Alopecia | 17 (56.7) | 2 (6.7) | 0 (0.0) | 0 (0.0) |
| Increased ALT level | 15 (50.0) | 1 (3.3) | 4 (13.3) | 0 (0.0) |
| Thrombocytopenia | 12 (40.0) | 8 (26.7) | 3 (10.0) | 0 (0.0) |
| Anemia | 12 (40.0) | 6 (20.0) | 2 (6.7) | 0 (0.0) |
| Anorexia | 7 (23.3) | 3 (10.0) | 1 (3.3) | 0 (0.0) |
| Fatigue | 6 (20.0) | 4 (13.3) | 0 (0.0) | 0 (0.0) |
| Increased AST level | 6 (20.0) | 1 (3.3) | 8 (26.7) | 0 (0.0) |
| Hypothyroidism | 5 (16.7) | 2 (6.7) | 0 (0.0) | 0 (0.0) |
| Blood bilirubin level increase | 5 (16.7) | 1 (3.3) | 3 (10.0) | 1 (3.3) |
| Epistaxis | 4 (13.3) | 1 (3.3) | 0 (0.0) | 0 (0.0) |
| Gum bleeding | 4 (13.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Leukopenia | 3 (10.0) | 9 (30.0) | 12 (40.0) | 6 (20.0) |
| Laryngeal hemorrhage | 3 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Fever | 2 (6.7) | 7 (23.3) | 0 (0.0) | 0 (0.0) |
| Pruritus | 2 (6.7) | 3 (10.0) | 0 (0.0) | 0 (0.0) |
| Vomiting | 2 (6.7) | 1 (3.3) | 0 (0.0) | 0 (0.0) |
| Hypertension | 1 (3.3) | 3 (10.0) | 2 (6.7) | 0 (0.0) |
| Diarrhea | 1 (3.3) | 3 (10.0) | 0 (0.0) | 0 (0.0) |
| Neutropenia | 0 (0.0) | 4 (13.3) | 12 (40.0) | 13 (43.3) |
| Rash | 0 (0.0) | 1 (3.3) | 2 (6.7) | 0 (0.0) |
| Urticaria | 0 (0.0) | 1 (3.3) | 1 (3.3) | 0 (0.0) |
| Febrile neutropenia | 0 (0.0) | 0 (0.0) | 3 (10.0) | 0 (0.0) |
| Myocarditis | 0 (0.0) | 0 (0.0) | 1 (3.3) | 0 (0.0) |
| Toxic epidermal necrolysis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.3) |
Treatment‐related adverse events observed in ≥10% of the patients and all grade 3‐4 adverse events are listed. No grade 5 adverse events were recorded.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.